Animal, Human Studies Support InSea2 for Diabetes Management

October 18, 2011

InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.

InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.

In the first study, published in Food Research International, in vitro experiments demonstrated InSea2’s mechanism of action against alpha-amylase and alpha-glucosidase. An in vivo experiment on laboratory animals also demonstrated InSea2’s ability to increase postprandial blood sugar by 90% while reducing insulin secretion by 40%.

InSea2 was also the focus of a human trial published in Applied Physiology, Nutrition, and Metabolism in which consumption of the ingredient complex significantly lowered postprandial blood glucose response by 48% and insulin secretion by 12%. InnoVactiv states that insulin sensitivity was also increased by 12% in the trial.

Related Content:

Blood Sugar